Liz Barrett, UroGen CEO, at the 2019 Forbes Healthcare Summit (Steven Ferdman/Getty Images)
August 27, 2020 09:27 AM EDTUpdated 10:09 AM
R&D

That pipeline Ab­b­Vie ac­quired in the $63B Al­ler­gan buy­out? It’s not do­ing so well

John Carroll

Editor & Founder

An­oth­er Al­ler­gan project picked up by Ab­b­Vie in their $63 bil­lion buy­out has turned sour.

Uro­Gen $URGN re­port­ed Thurs­day morn­ing that a Phase II …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times